About: ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Sector: Healthcare
Industry: Biotechnology
Latest price: $1.85 (-7.04%)
PROKNASDAQProKidney Corp.
ProKidney Corp. share price
PROK price activity
Last Price
$1.850
Change (24hr)
-0.14 USD (-7.04%)
Volume
1.41M
Volume (4w avg)
-
Open
$1.98
Day Range
$1.83 - $1.99
Previous Close
$1.99
Last Trade
09 Sep, 8:00 pm GMT+0
Delayed
09 Sep, 8:00 pm GMT+0
PROK price performance
Delayed
09 Sep, 8:00 pm GMT+0
PROK Market Signals